- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04295720
Treatment of Post-Chemo Cognitive Impairment w/Transcranial Magnetic Stimulation (Chemobrain TMS)
Treatment of Post-Chemotherapy Cognitive Impairment With Transcranial Magnetic Stimulation (Chemobrain TMS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Transcranial magnetic stimulation (TMS) is a safe and non-invasive brain stimulation technique. It uses a magnetic coil to stimulate brain tissue painlessly using only a magnet (no electrodes or electrical wires) in a procedure that does not involve any surgery or sedation. TMS is currently FDA approved to treat depression and migraines. Although this technology is applicable to many other brain conditions as well, it has not been systematically examined in individuals with "Chemo-brain". Chemo-brain or Post-Chemotherapy Cognitive Impairment (PCCI) is defined as cognitive changes including impairment of memory, learning, concentration, reasoning, executive function, attention and visuo visio-spatial skills that occur during or after chemotherapy treatment.
In this study, investigators will:
- use high-resolution magnetic resonance imaging (MRI) of individuals' brains to determine precisely where to place the TMS magnetic coil in order to stimulate the target brain region based off their unique brain structure.
- use TMS to stimulate the target region of the brain.
- take high-resolution MRI pictures of the brain both baseline and post-TMS to study whether the brain activity of the target region changes as a result of the TMS stimulation.
- perform neuropsychological tasks baseline and post-TMS to study if performance is improved following stimulation of the target brain region.
- collect data from completing Frailty assessments, baseline and post-TMS.
- study the short-term and long-term treatment effects.
- collect subject's daily activity and sleep/wake patterns from watch style device (http://www.actigraphy.com/solutions/actiwatch/actiwatch-plus-specifications.html).
- perform behavioral assessments, baseline and post-TMS, to study whether there are measurable changes following stimulation of the target brain region.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- University of Arizona Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult (>=18).
- PCCI diagnosis (see information below).
- Right Handed (We will not enroll left-handed dominant people because they tend to have more symmetric brain function and thus targeting the left frontal region may not be as effective.)
- English speaking.
- Cancer treatment completed and considered curative with the exception of endocrine therapy after chemotherapy.
- Able to attend daily intervention (Monday-Friday) for 2 weeks.
- Not enrolled in another interventional study within 6 months prior to beginning this study.
Exclusion Criteria:
- Pregnancy or thinking of becoming pregnant.
- Undergoing active treatment for cancer.
- Routine contraindications for MRI (including incompatible medical implants or metal fragments in the body at risk for migration or heating with application of the magnetic field) including severe claustrophobia.
- History of brain metastasis or other brain tumor.
- History of stroke or traumatic brain injury.
- Frequent or severe headaches.
- Cognitive or mood disorder prior to chemotherapy (i.e. dementia or depression).
- History of epilepsy, or other seizure disorders.
- History mental health disorders, such as substance misuse, bipolar disorder or psychosis.
- Taking medication for seizures or that could lower seizure threshold if withdrawn.
- Inability to complete neuropsychological testing.
- Prior treatment with rTMS. We will enroll subjects without prior experience with rTMS.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transcranial magnetic stimulation (TMS)
We propose to test the efficacy of rTMS for the treatment of PCCI.
Efficacy measures will include baseline and post-rTMS neuropsychological testing, functional MRI and biometry data using body worn sensors.
|
Subjects will undergo testing at baseline prior to TMS treatments and once more at the end of the 2-week intervention.After the conclusion of baseline data acquisition, the research team will analyze each participant's unique structural and functional connectivity patterns to determine stimulation site for TMS in future study sessions. The subjects will receive 10-sessions (1 session per day, M-F over 2 consecutive weeks). The treatment itself lasts approximately only 190 seconds. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Memory Testing
Time Frame: 14 days
|
Efficacy measures will include baseline and post-rTMS neuropsychological testing. The Outcome Measure is the difference between the pre and post scores of the following Neuropsychological tests. The score from each test was added together to come up with a single value. A higher score indicates better performance. Minimum is score of 0 and maximum is not applicable (a timed test). The Neuropsychological tests we analyzed: Forward Digit Span Backward Digit Span Rey Auditory Verbal Learning Test Verbal Fluency Task Stroop Color-Word Interference Task |
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Test for improved brain functional connectivity on fMRI.
Time Frame: Two weeks
|
Take high-resolution MRI pictures of the brain both baseline and post-TMS to study whether the brain activity of the target region changes as a result of the TMS stimulation.
|
Two weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Phillip Kuo, MD, University of Arizona
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1911180572
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemo-brain
-
UNC Lineberger Comprehensive Cancer CenterEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCognitive Decline | Chemo-brainUnited States
-
Vanderbilt University Medical CenterCompletedBreast Cancer | Chemotherapy-related Cognitive Impairment | Chemo Fog | Chemo Brain | ChemobrainUnited States
-
University of Alabama at BirminghamNot yet recruitingGynecologic Cancer | Chemotherapy Effect | Chemo-brain | Cancer-related Cognitive Difficulties
-
Ospedale San Carlo BorromeoAssociazione Oncologica Milanese AmoLaVita ONLUSNot yet recruitingCognitive Impairment | Chemo-brain | Haematological MalignancyItaly
-
Joseph McCollomIndiana University School of MedicineRecruitingCognitive Impairment | Cognitive Dysfunction | Cognitive Change | Chemotherapy Effect | Cognitive Decline | Chemo-brain | Neoplasm, Colorectal | Chemo FogUnited States
-
Tang-Du HospitalHealth Science Center of Xi'an Jiaotong UniversityRecruitingBreast Cancer | Endocrine Therapy | Chemo-brainChina
-
Vanderbilt University Medical CenterUniversity of UtahRecruitingChemotherapy-Related Cognitive Impairment | Chemo-brainUnited States
-
Massachusetts General HospitalRecruitingBreast Cancer | Chemo-brain | Impaired CognitionUnited States
-
Groupe Hospitalier Paris Saint JosephCompletedPeripheric Neuropathy | Chemo-induced NeuropathyFrance
Clinical Trials on Transcranial magnetic stimulation (TMS)
-
Emory UniversityNational Institute of Mental Health (NIMH)Recruiting
-
Centre Hospitalier St AnneNot yet recruitingTreatment Resistant Schizophrenia
-
University of California, San DiegoNational Institutes of Health (NIH)RecruitingMajor Depressive DisorderUnited States, Australia
-
Northwestern UniversityCompletedHealthyUnited States
-
University of FloridaActive, not recruiting
-
Huashan HospitalUnknown
-
University of ManitobaRecruiting
-
University of PennsylvaniaCompletedAttention Deficit Disorder With Hyperactivity (ADHD)United States
-
Beth Israel Deaconess Medical CenterTerminated
-
Northwestern UniversityRecruiting